Gilead Sciences Inc
NASDAQ: GILD
$92.41
+$1.06 (+1.2%)
Closing Price on November 27, 2024
GILD Articles
ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many of...
Published:
courtesy of Sirius XM RadioShort sellers continue to hold huge positions not only in troubled companies like BlackBerry Ltd. (NASDAQ: BBRY), but also in such tech giants as Intel. As of April 30, the...
Published:
In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six physicians. They favor four top stocks now as best positioned for continued...
Published:
bfishshadow via Wikimedia CommonsShort sellers continue to hold huge positions not only in troubled companies like BlackBerry and Staples, but also in blue chips like Microsoft. As of April 15, the...
Published:
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it all back and then some through April 15.
Published:
ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue...
Published:
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Published:
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of stocks that are rated...
Published:
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild card report...
Published:
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after years of...
Published:
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.
Published:
thinkstockApril 11, 2014: Markets opened lower on Friday with the S&P 500 and the Nasdaq Composite breaking into positive territory late in the morning. Unfortunately neither index could hold the...
Published:
Last Updated:
In a new report, RBC has a list of stocks with some of the largest percentage drops and the lowest forward price-to-earnings (P/E) ratios. This may serve as shopping list for the second half of the...
Published:
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep...
Published:
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of...
Published: